Plus Therapeutics Q2 net loss narrows to $1.5M; FDA clears Ph1/Part B of ReSPECT-LM

PLUS THERAPEUTICS, INC.

2023-Q2 EPS reported -$2.60

Q2 2023 net loss of $1.5M ($0.59/share) vs $5.3M ($3.56/share) in Q2 2022.
Cash balance $10.9M at June 30, 2023, down from $18.1M at Dec 31, 2022; expects $1.9M CPRIT grant soon.
FDA approval to advance ReSPECT-LM trial to Phase 1/Part B for leptomeningeal metastases.
Total operating expenses fell 35% YoY to $3.3M due to lower R&D spend after initial cGMP work.
New VP of Clinical Operations Pius Maliakal appointed; expanded Piramal Pharma supply collaboration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PLUS THERAPEUTICS, INC. reported the second quarter ended June 30, 2023 results: net income $(1.5) million, EPS $(0.59) per share.

Period: the second quarter ended June 30, 2023
Net income: $(1.5) million
EPS: $(0.59) per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $(1.5) million, or $(0.59) per share

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-042421

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.